Ketone compounds and compositions for cholesterol management and related uses

A method for treating diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, or insulin resistance, relating to diabetes, comprising administering to a patient in need of such treatment a therapeutically effective amount of a compound selected from a group consisting of:

• t-butyl-1-[9-[1-(tert-butyoxycarbonyl)cyclopropyl]-5-oxononyl]-1-cyclopropanecarboxylate;
• 11-(1-carboxycyclopropyl)-2,2-dimethyl-7-oxoundecanoic acid;
• 1-[9-(1-carboxycyclopropyl)-5-oxononyl]-1-cyclopropanecarboxylic acid;
• 11-(1-carboxycyclobutyl)-2,2-dimethyl-7-oxoundecanoic acid;
• 1-[9-(1-carboxycyclobutyl)-5-oxononyl]-1-cyclobutanecarboxylic acid;
• 1-[9-(1-carboxycyclopentyl)-5-oxononyl]-1-cyclopentylcarboxylic acid;
• 13-(1-carboxycyclopropyl)-2,2-dimethyl-8-oxotridecanoic acid;
• 1-[11-(1-carboxycyclopropyl)-6-oxoundecyl]-1-cyclopropanecarboxylic acid;
• and
• 1-[11-(1-carboxycyclopentyl)-6-oxoundecyl]-1-cyclopentanecarboxylic acid;
• or a pharmaceutically acceptable salt thereof.